Mutant

Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

Retrieved on: 
Wednesday, March 6, 2024
Paper, Combination therapy, Breast cancer, SAN, Woman, FDA, Animal, Proteolysis targeting chimera, Behavior, Therapy, Selective estrogen receptor degrader, Enzyme inhibitor, CNS, Pharmacokinetics, Survival, MOA, Research, Mutant, Pharmaceutical industry

The paper, titled “Palazestrant (OP-1250), a Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination”, describes the scientific background underlying the design, discovery and optimization of palazestrant.

Key Points: 
  • The paper, titled “Palazestrant (OP-1250), a Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination”, describes the scientific background underlying the design, discovery and optimization of palazestrant.
  • “What’s even more exciting is to see how faithfully the pre-clinical research predicted the behavior of palazestrant now that it is in late-stage clinical development.
  • In mouse xenograft models, palazestrant demonstrated excellent pharmacokinetics, was well tolerated, showed synergy with CDK4/6 inhibitors, and was highly effective at reducing tumor growth in both wild-type and ESR1-mutant ER+ breast cancer.
  • In addition, in an ESR1-mutant intercranial xenograft model, palazestrant inhibited tumor growth and improved survival of animals with CNS metastases, even after stopping drug treatment.

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, August 8, 2023
CCCC, Pharming, G&A, BRAF V600, Patient, Research and development, R, Disease, Multiple myeloma, Drug discovery, Lung cancer, Combination therapy, International Conference on Afghanistan, London (2006), Security (finance), BRD9, FDA, Conference, Safety, Appointment, Roche, BRAF, Medicine, NSCLC, Finance, Controlled Impact Demonstration, Administration, Colorectal cancer, Research, Therapy, Synovial sarcoma, Drug development, CRC, ICML, Clinical trial, Lymphoma, NHL, CNS, Dexamethasone, ASCO, Public expenditure, American Society of Clinical Oncology, Melanoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, Pharmaceutical industry, Cryptocurrency, Fine chemical, Vaccine, Video game, Biogen, Calico, IND, Mutant

WATERTOWN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today reported financial results for the second quarter ended June 30, 2023, as well as recent business highlights.

Key Points: 
  • Revenue: Total revenue for the second quarter of 2023 was $2.7 million, compared to $13.8 million for the second quarter of 2022.
  • Research and Development (R&D) Expense: R&D expense for the second quarter of 2023 was $29.9 million, compared to $31.3 million for the second quarter of 2022.
  • General and Administrative (G&A) Expense: G&A expense for the second quarter of 2023 was $10.3 million, compared to $9.9 million for the second quarter of 2022.
  • Net loss per share for the second quarter of 2023 was $0.73 compared to $0.56 for the second quarter of 2022.

Redefining Off-road Versatility: Dunlop Motorcycle Tires Introduces the TrailMax Raid

Retrieved on: 
Thursday, July 20, 2023
Mutant, JLB, Motorcycle, CTCS, Raid, Parker Jointless, Road, Tire manufacturing

RANCHO CUCAMONGA, Calif., July 20, 2023 /PRNewswire-PRWeb/ -- Dunlop Motorcycle Tires is excited to introduce the all-new Dunlop Trailmax Raid. This latest addition to the Trailmax family is designed for 40% on-road and 60% off-road use, combining expertise and technology from Dunlop's extensive line of tires. The Trailmax Raid is suitable for a wide range of bikes from mid-size dual sports to large adventure bikes, offering exceptional off-road capabilities paired with outstanding wet weather grip and adventure touring performance.

Key Points: 
  • Dunlop Motorcycle Tires is proud to present the Trailmax Raid, an innovative blend of on-road comfort and off-road resilience.
  • RANCHO CUCAMONGA, Calif., July 20, 2023 /PRNewswire-PRWeb/ -- Dunlop Motorcycle Tires is excited to introduce the all-new Dunlop Trailmax Raid .
  • This latest addition to the Trailmax family is designed for 40% on-road and 60% off-road use, combining expertise and technology from Dunlop's extensive line of tires .
  • The Trailmax Raid's design was inspired by Dunlop's popular D908RR Rally Raid, a tire designed for aggressive adventure and cross-country conditions.

Affini-T Therapeutics to Present Novel CRISPR Gene Editing Data from its Oncogenic Driver Program Targeting KRAS at the American Society of Gene and Cell Therapy 26th Annual Meeting

Retrieved on: 
Tuesday, May 9, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, KRAS, Gene, Gene editing, Mutant, Cell, Sensitivity, Patient, Annual general meeting, American Society of Gene and Cell Therapy, Therapy, Society, Safety, Vaccine

Affini-T Therapeutics, Inc. , a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that preclinical data for its oncogenic driver program targeting KRAS G12D, AFNT–212, will be presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles, California.

Key Points: 
  • Affini-T Therapeutics, Inc. , a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that preclinical data for its oncogenic driver program targeting KRAS G12D, AFNT–212, will be presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles, California.
  • “Our mission is to address the significant unmet needs of patients with hard-to-treat solid tumors by advancing precision immunotherapies that target oncogenic driver mutations,” said Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics.
  • “We believe gene editing is an important tool in the development of cell therapies as it allows for precise and targeted modifications within cells, aimed to improve safety and activity of these therapies.
  • We look forward to presenting encouraging preclinical data for our gene-edited KRAS G12D-targeting TCR-T cell therapy, AFNT-212, at ASGCT this year.”
    Poster presentation details are as follows:
    Abstract: #1691, May 19, 12:00-2:00 pm PT: Novel CRISPR-Associated Gene Editing Systems Enable Efficient and Specific TRAC/TRBC Knockout Triggering Robust Expression and Sensitivity of a T Cell Receptor Specific for Mutant KRAS G12D – Presenting Author: Ankit Gupta, Ph.D., Director of Gene Editing, Affini-T Therapeutics

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, May 4, 2023
Synovial sarcoma, PK, AACR, PD, CRC, CCCC, Cancer research, Biogen, Roche, Clinical trial, NHL, BRAF, G&A, NSCLC, Finance, Lung cancer, BRAF V600, Dexamethasone, Combination therapy, Public expenditure, Ongo, Investigational New Drug, Patient, Administration, Colorectal cancer, Melanoma, Annual general meeting, Research and development, BRD9, Research, R, Therapy, Security, IND, Society, Conference, Disease, Pharmaceutical industry, Cryptocurrency, Fine chemical, Medical imaging, Video game, Mutant

WATERTOWN, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today reported financial results for the first quarter ended March 31, 2023, as well as recent business highlights.

Key Points: 
  • Revenue: Total revenue for the first quarter of 2023 was $3.8 million, compared to $7.7 million for the first quarter of 2022.
  • Research and Development (R&D) Expense: R&D expense for the first quarter of 2023 was $29.0 million, compared to $26.2 million for the first quarter of 2022.
  • General and Administrative (G&A) Expense: G&A expense for the first quarter of 2023 was $10.9 million, compared to $12.8 million for the first quarter of 2022.
  • Net loss per share for the first quarter of 2023 was $0.71 compared to $0.65 for the first quarter of 2022.

Playmates Toys Reveals Official Action Figures for Paramount Pictures, Nickelodeon Movies and Point Grey Productions’ Highly Anticipated Film “Teenage Mutant Ninja Turtles: Mutant Mayhem”

Retrieved on: 
Tuesday, March 7, 2023
Film & Motion Pictures, Children, Other Retail, Online Retail, Licensing (Entertainment), General Entertainment, Entertainment, Retail, Toys, Consumer, Parenting, Giant, Teenage Mutant Ninja Turtles, Playmates, Teenage Mutant Ninja Turtles action figures, Playmates Toys, Attitude, Teenage Mutant Ninja Turtles: Mutant Mayhem, Nickelodeon Movies, Multimedia, Weapon, Fever, New Yorker, Paramount Pictures, Mutant, Toy, Film industry, Turtle

Following the world premiere of a teaser preview for “Teenage Mutant Ninja Turtles: Mutant Mayhem,” Playmates Toys today revealed a sampling of its Ninja Turtles action figures, vehicles, and role play toys based on the late summer 2023 film.

Key Points: 
  • Following the world premiere of a teaser preview for “Teenage Mutant Ninja Turtles: Mutant Mayhem,” Playmates Toys today revealed a sampling of its Ninja Turtles action figures, vehicles, and role play toys based on the late summer 2023 film.
  • View the full release here: https://www.businesswire.com/news/home/20230307005892/en/
    Playmates Toys today revealed a sampling of its Ninja Turtles action figures, vehicles and roleplay toys based on this summer's highly anticipated film “Teenage Mutant Ninja Turtles: Mutant Mayhem."
  • (Photo: Nickelodeon/Playmates Toys)
    Playmates Toys has the ultimate line of Teenage Mutant Ninja Turtles action figures, vehicles, and iconic role play weapons based on the upcoming film.
  • Teenage Mutant Ninja Turtles: Mutant Mayhem Giant Figures, 12-inch versions of our heroes, fully articulated, poseable, and each comes with their iconic weapons.

Dimitrius Oliveira appointed as CEO of Atento and Anil Bhalla as Executive Chairman of the Board

Retrieved on: 
Wednesday, November 30, 2022
Human, Concentrix, Specialization, Telecommunication, Harvard Business School, Constantin Dimitriu-Dovlecel, Universidade de Mogi das Cruzes, Advertising, Bankruptcy, Mount Everest, Contax, Health, Risk, RSM, Growth, Magic Quadrant, Genesys, Major airlines of the United States, NYSE, Avaya, Ericsson, Multimedia, MBA, Marketing, Senior, Franchise, CRM, Intellectual property, India, Mutant, Management, Atento

Mr. Oliveira has also been appointed as a member of the Board of Directors of the Company.

Key Points: 
  • Mr. Oliveira has also been appointed as a member of the Board of Directors of the Company.
  • "It is a tremendous honor to be appointed CEO and I am very excited for the opportunities that lie ahead for Atento,"said Dimitrius Oliveira.
  • Prior to joining Mutant, Dimitrius served as Atento Global Commercial Director and Brazil Multisector Director from 2015 to 2017.
  • In order to ensure a smooth leadership transition, the Company has appointed Anil Bhalla as Executive Chairman to lead key strategic transformational initiatives and specific growth objectives.

Mutant Froggo - the new modern-day superheroes are here to save the cryptocurrency world – and they did not come to play!

Retrieved on: 
Friday, September 23, 2022
Rest, NFT, Diamond, IOS, Mutant, Collection, Contract, Decentralized finance, Monolithic kernel, Veteran, Data management, Non-fungible token, Ecosystem, Research, GLOBE, NO, Web3, Cryptocurrency, Risk management

Singapore, Singapore, Sept. 23, 2022 (GLOBE NEWSWIRE) -- The Mutant Froggo project is the latest and hottest addition to the cryptocurrency space.

Key Points: 
  • Singapore, Singapore, Sept. 23, 2022 (GLOBE NEWSWIRE) -- The Mutant Froggo project is the latest and hottest addition to the cryptocurrency space.
  • The Mutant Froggo team works tirelessly solely for the benefit of its investors and future holders.
  • Including but not limited to; their NFT Collection, Mutant Mobile Application, Mutant Marketplace, Mutant Froggo Comic, Future Jump2Earn Developments, & the list goes on!
  • The Mutant Froggo is definitely a diamond in the rough, a project everyone will look out for in the future!

HIT-BOY & JAMES FAUNTLEROY JOIN KINGSHIP AS CO-EXECUTIVE PRODUCERS AND SONGWRITERS

Retrieved on: 
Monday, September 12, 2022
Dolla, Rider, Billboard 200, Song of the Year, KING, Discord, Engineering, NFT, NAACP Image Awards, That's What I Like, Little Lord Fauntleroy, Mutant, BTS, SZA, Partnership, Billboard, Industry, Music, Curriculum, Nas, Animation, Rihanna, Sound, Usher, Student, Hall of Fame (Big Sean album), Detroit 2, Grammy Award for Producer of the Year, Non-Classical, Non-fungible token, Record, BET, Collection, Complex, Bass, Year, Rocky, Nightclub, Cryptocurrency, Renaissance, Arnell

SANTA MONICA, Calif., Sept. 12, 2022 /PRNewswire/ -- KINGSHIP, the NFT supergroup signed to 10:22PM, announced today that two chart-topping and award-winning music producers and songwriters Hit-Boy and James Fauntleroy have signed on as the group's co-executive producers and sonic creative team, overseeing the evolution of the group's music direction and sound. Together, they will work with Arnell, the group's Mutant DJ and Producer.

Key Points: 
  • "I'm always looking to push things forward musically," said Hit-Boy, "and this is a great opportunity to do something new in the web3 space."
  • Fauntleroy added, "It's so exciting to be a part of something historical and ambitious.
  • "I'm incredibly thankful that Hit-Boy and James Fauntleroy, two of the most influential and creative geniuses in the entire industry, are coming together to develop the music and sound for KINGSHIP."
  • As one of the music industry's most sought out producers and artists, the California-bred Hit-Boy has more than earned his moniker.

KINGSHIP™ and Mars Partner on Limited Edition M&M'S® Featuring the World's First NFT Supergroup

Retrieved on: 
Wednesday, August 24, 2022
Technology, EXTRA, Music, Jade McNelis, Non-fungible token, Consumer, Anicura, Twitter, Originality, Mutant, It's a Long Way to the Top (If You Wanna Rock 'n' Roll), Amphitheatre, Time, Collection, Royal, DNA, PETS, Commerce, Queen, NFT, Gold, Blockchain, Industry, KING, Hospital Insurance and Diagnostic Services Act, Partnership, Food, M&M, Rock, LinkedIn, Multimedia, Universal Music Group, Snack, Instagram, Discord, KIND, Bass, Uncle Ben's, VCA, YouTube, Lock and key, Taste, Candy, Family, Nightclub, Entertainment, Cryptocurrency, Facebook, Mars, Arnell

SANTA MONICA, Calif., Aug. 24, 2022 /PRNewswire/ -- KINGSHIP™, the NFT supergroup created by 10:22PM™, consisting of three Bored Apes and one Mutant Ape, today announced they will appear on limited edition boxes of M&M'S® in honor of KINGSHIP's mythological tour rider containing required backstage items, which always includes M&M'S candies of all colors.

Key Points: 
  • In all cases, M&M'S were involved and necessary accessories to some of the greatest moments in rock history.
  • KINGSHIP Captain, KING, Arnell and Hud are seriously smart and of discerning taste, making sure to request bowls of colorful M&M'S within their precious show rider.
  • These physical collectible boxes have been created for fans of both KINGSHIP and M&M'S and are only available for a limited time.
  • Additionally, there will be 6,000 gift jars of the candies, available TODAY to fans in the U.S. for a limited time at https://mms.com/kingship .